FEATURED COMPANIES
- Arrayjet Ltd
- Bjs Biotechnologies Ltd
- Breast Cancer Campaign
- Cancer Vaccines Ltd
- Randox Laboratories Ltd
- MORE
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Almac Diagnostic Services Ltd (Almac Diagnostic Services), a subsidiary of Almac Group Ltd, is a medical diagnostic company that discovers, develops and commercializes diagnostic tests including companion diagnostics. The company provides products pipeline such as ColDx, DDRD, AADx, prostate Dx and MEK Dx, among others. It offers ColDx, a prognostic assay for stage II and III colon cancer, and DDRD, is a predictive assay for immune-oncology and DNA damaging agent. Almac Diagnostic Services provides pre-clinical biomarker discovery to companion diagnostic development including regulatory submissions and commercialization. The company provides applications such as patient selection, and are utilised in phase I to phase III registrational clinical trials. It operates laboratories in the US and the UK. Almac Diagnostic Services is headquartered in Craigavon, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
Almac Diagnostic Services Ltd (Almac Diagnostic Services), a subsidiary of Almac Group Ltd, is a medical diagnostic company that discovers, develops and commercializes diagnostic tests including companion diagnostics. The company provides products pipeline such as ColDx, DDRD, AADx, prostate Dx and MEK Dx, among others. It offers ColDx, a prognostic assay for stage II and III colon cancer, and DDRD, is a predictive assay for immune-oncology and DNA damaging agent. Almac Diagnostic Services provides pre-clinical biomarker discovery to companion diagnostic development including regulatory submissions and commercialization. The company provides applications such as patient selection, and are utilised in phase I to phase III registrational clinical trials. It operates laboratories in the US and the UK. Almac Diagnostic Services is headquartered in Craigavon, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Almac Diagnostic Services Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Arrayjet Ltd
- Bjs Biotechnologies Ltd
- Breast Cancer Campaign
- Cancer Vaccines Ltd
- Randox Laboratories Ltd
- MORE
Almac Diagnostic Services Ltd Company Overview
- Almac Diagnostic Services Ltd Company Snapshot
Almac Diagnostic Services Ltd Pipeline Products and Ongoing Clinical Trials Overview
Almac Diagnostic Services Ltd - Pipeline Analysis Overview
Almac Diagnostic Services Ltd - Key Facts
Almac Diagnostic Services Ltd - Major Products and Services
- Almac Diagnostic Services Ltd Pipeline Products by Development Stage
Almac Diagnostic Services Ltd Pipeline Products Overview
2-Gene qPCR LDT
- 2-Gene qPCR LDT Product Overview
ALM AADx Assay
- ALM AADx Assay Product Overview
Almac EMT Assay
- Almac EMT Assay Product Overview
Angiogenesis Subtype Diagnostic Assay
- Angiogenesis Subtype Diagnostic Assay Product Overview
Diagnostic Test - Ovarian Cancer
- Diagnostic Test - Ovarian Cancer Product Overview
DNA Damage Response Deficiency Assay - Breast Cancer
- DNA Damage Response Deficiency Assay - Breast Cancer Product Overview
DNA Damage Response Deficiency Assay - Colorectal Cancer
- DNA Damage Response Deficiency Assay - Colorectal Cancer Product Overview
DNA Damage Response Deficiency Assay - Esophageal Cancer
- DNA Damage Response Deficiency Assay - Esophageal Cancer Product Overview
DNA Damage Response Deficiency Assay - Ovarian Cancer
- DNA Damage Response Deficiency Assay - Ovarian Cancer Product Overview
NanoStrings’s nCounter Dx Analysis System with FLEX - Companion Diagnostic Assay
- NanoStrings’s nCounter Dx Analysis System with FLEX - Companion Diagnostic Assay Product Overview
Next-Generation Sequencing Based Companion Diagnostic Assay
- Next-Generation Sequencing Based Companion Diagnostic Assay Product Overview
Pan-Cancer Companion Diagnostic Assay
- Pan-Cancer Companion Diagnostic Assay Product Overview
Predictive Assay - Immuno-oncology
- Predictive Assay - Immuno-oncology Product Overview
Prognostic Test - Early Stage Lung Cancer
- Prognostic Test - Early Stage Lung Cancer Product Overview
Prognostic Test - NSCLC
- Prognostic Test - NSCLC Product Overview
Prostate Cancer Metastatic Assay
- Prostate Cancer Metastatic Assay Product Overview
RSPO3 CLIA Assay
- RSPO3 CLIA Assay Product Overview
Almac Diagnostic Services Ltd - Key Competitors
Almac Diagnostic Services Ltd - Key Employees
Almac Diagnostic Services Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
Recent Developments
- Almac Diagnostic Services Ltd, Recent Developments
- Sep 26, 2019: Almac’s unique gene expression report enables cancer researchers to discover exciting new insights
- Jun 05, 2019: Almac Group announces CE mark of diagnostic assay to support Turning Point Therapeutics’ pivotal TRIDENT-1 clinical trial
- May 06, 2019: Turning Point Therapeutics and Almac Diagnostic Services announce approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study
- Apr 23, 2019: Almac forms alliance with academia for new oesophageal cancer test
- Apr 18, 2019: Almac Group partner with Queen’s researchers to pioneer potentially life-changing Oesophageal Cancer test
- Mar 27, 2019: Almac Group launches upgraded version of claraT - a unique, software-driven gene expression report
- Oct 19, 2018: Almac Group launches claraT - A unique, software-driven gene expression report
- Feb 12, 2018: DNAnexus Launches NGS Clinical Trial Solution
- Oct 23, 2017: Queens University Belfast Leads Largest Study of its Kind to Transform Prostate Cancer Treatment
- Jun 13, 2017: Almac Group Awarded U.S. Patents for Ground-breaking “DDRD” Assay
Appendix
- Methodology
- About the Publisher
- Contact
- Disclaimer
List of Tables
- Almac Diagnostic Services Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Almac Diagnostic Services Ltd Pipeline Products by Equipment Type
- Almac Diagnostic Services Ltd Pipeline Products by Indication
- Almac Diagnostic Services Ltd, Key Facts
- Almac Diagnostic Services Ltd, Major Products and Services
- Almac Diagnostic Services Ltd Number of Pipeline Products by Development Stage
- Almac Diagnostic Services Ltd Pipeline Products Summary by Development Stage
- 2-Gene qPCR LDT - Product Status
- 2-Gene qPCR LDT - Product Description
- ALM AADx Assay - Product Status
- ALM AADx Assay - Product Description
- Almac EMT Assay - Product Status
- Almac EMT Assay - Product Description
- Angiogenesis Subtype Diagnostic Assay - Product Status
- Angiogenesis Subtype Diagnostic Assay - Product Description
- Diagnostic Test - Ovarian Cancer - Product Status
- Diagnostic Test - Ovarian Cancer - Product Description
- DNA Damage Response Deficiency Assay - Breast Cancer - Product Status
- DNA Damage Response Deficiency Assay - Breast Cancer - Product Description
- DNA Damage Response Deficiency Assay - Colorectal Cancer - Product Status
- DNA Damage Response Deficiency Assay - Colorectal Cancer - Product Description
- DNA Damage Response Deficiency Assay - Esophageal Cancer - Product Status
- DNA Damage Response Deficiency Assay - Esophageal Cancer - Product Description
- DNA Damage Response Deficiency Assay - Ovarian Cancer - Product Status
- DNA Damage Response Deficiency Assay - Ovarian Cancer - Product Description
- NanoStrings’s nCounter Dx Analysis System with FLEX - Companion Diagnostic Assay - Product Status
- NanoStrings’s nCounter Dx Analysis System with FLEX - Companion Diagnostic Assay - Product Description
- Next-Generation Sequencing Based Companion Diagnostic Assay - Product Status
- Next-Generation Sequencing Based Companion Diagnostic Assay - Product Description
- Pan-Cancer Companion Diagnostic Assay - Product Status
- Pan-Cancer Companion Diagnostic Assay - Product Description
- Predictive Assay - Immuno-oncology - Product Status
- Predictive Assay - Immuno-oncology - Product Description
- Prognostic Test - Early Stage Lung Cancer - Product Status
- Prognostic Test - Early Stage Lung Cancer - Product Description
- Prognostic Test - NSCLC - Product Status
- Prognostic Test - NSCLC - Product Description
- Prostate Cancer Metastatic Assay - Product Status
- Prostate Cancer Metastatic Assay - Product Description
- RSPO3 CLIA Assay - Product Status
- RSPO3 CLIA Assay - Product Description
- Almac Diagnostic Services Ltd, Key Employees
- Almac Diagnostic Services Ltd, Other Locations
- Glossary
List of Figures
- Almac Diagnostic Services Ltd Pipeline Products by Equipment Type
- Almac Diagnostic Services Ltd Pipeline Products by Development Stage
Note: Product cover images may vary from those shown
LOADING...
- Randox Laboratories Ltd
- Cancer Vaccines Ltd
- Cambridge Clinical Laboratories Ltd
- Breast Cancer Campaign
- Bjs Biotechnologies Ltd
- Arrayjet Ltd
Note: Product cover images may vary from those shown